
Egetis Therapeutics AB (publ) (EGTX.ST)
EGTX.ST Stock Price Chart
Explore Egetis Therapeutics AB (publ) interactive price chart. Choose custom timeframes to analyze EGTX.ST price movements and trends.
EGTX.ST Company Profile
Discover essential business fundamentals and corporate details for Egetis Therapeutics AB (publ) (EGTX.ST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Apr 2011
Employees
38.00
Website
https://www.egetis.comCEO
Nicklas Westerholm
Description
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
EGTX.ST Financial Timeline
Browse a chronological timeline of Egetis Therapeutics AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 7 Nov 2025
Earnings released on 21 Aug 2025
Revenue for the quarter reached kr 14.50M , missing expectations by -12.12%.
Earnings released on 1 May 2025
EPS came in at -kr 0.20 surpassing the estimated -kr 0.24 by +16.67%, while revenue for the quarter reached kr 12.70M , missing expectations by -29.44%.
Earnings released on 26 Feb 2025
EPS came in at -kr 0.30 falling short of the estimated -kr 0.26 by -15.38%, while revenue for the quarter reached kr 10.80M , missing expectations by -32.50%.
Earnings released on 8 Nov 2024
EPS came in at -kr 0.30 matching the estimated -kr 0.30, while revenue for the quarter reached kr 9.40M , missing expectations by -41.25%.
Earnings released on 22 Aug 2024
EPS came in at -kr 0.20 surpassing the estimated -kr 0.29 by +31.03%, while revenue for the quarter reached kr 13.90M , beating expectations by +17.10%.
Earnings released on 3 May 2024
EPS came in at -kr 0.30 surpassing the estimated -kr 0.31 by +3.23%, while revenue for the quarter reached kr 12.10M , beating expectations by +8.33%.
Earnings released on 22 Feb 2024
EPS came in at -kr 0.30 matching the estimated -kr 0.30, while revenue for the quarter reached kr 32.60M , beating expectations by +110.32%.
Earnings released on 8 Nov 2023
EPS came in at -kr 0.30 falling short of the estimated -kr 0.21 by -42.86%, while revenue for the quarter reached kr 12.20M , beating expectations by +74.29%.
Earnings released on 22 Aug 2023
EPS came in at -kr 0.30 falling short of the estimated -kr 0.26 by -15.38%, while revenue for the quarter reached kr 5.90M , missing expectations by -5.60%.
Earnings released on 26 Apr 2023
EPS came in at -kr 0.30 falling short of the estimated -kr 0.28 by -7.14%, while revenue for the quarter reached kr 6.80M , beating expectations by +8.80%.
Earnings released on 22 Feb 2023
EPS came in at -kr 0.40 falling short of the estimated -kr 0.21 by -90.48%, while revenue for the quarter reached kr 5.60M , missing expectations by -46.05%.
Earnings released on 8 Nov 2022
EPS came in at -kr 0.30 falling short of the estimated -kr 0.18 by -66.67%, while revenue for the quarter reached kr 5.10M , missing expectations by -50.87%.
Earnings released on 19 Aug 2022
EPS came in at -kr 0.20 surpassing the estimated -kr 0.21 by +4.76%, while revenue for the quarter reached kr 4.66M , missing expectations by -55.11%.
Stock split effective on 27 Apr 2022
Shares were split 1089 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 26 Apr 2022
EPS came in at -kr 0.18 falling short of the estimated -kr 0.17 by -5.88%, while revenue for the quarter reached kr 7.10M , missing expectations by -28.98%.
Earnings released on 17 Feb 2022
EPS came in at -kr 0.18 falling short of the estimated -kr 0.17 by -5.88%, while revenue for the quarter reached kr 3.21M , missing expectations by -8.26%.
Earnings released on 4 Nov 2021
EPS came in at -kr 0.09 surpassing the estimated -kr 0.19 by +52.63%, while revenue for the quarter reached kr 6.21M .
Earnings released on 19 Aug 2021
EPS came in at -kr 0.18 falling short of the estimated -kr 0.17 by -5.88%, while revenue for the quarter reached kr 25.03M .
Earnings released on 22 Apr 2021
EPS came in at -kr 0.09 surpassing the estimated -kr 0.22 by +59.09%, while revenue for the quarter reached kr 3.79M .
Earnings released on 17 Feb 2021
EPS came in at -kr 0.64 , while revenue for the quarter reached kr 4.89M .
Earnings released on 11 Nov 2020
EPS came in at -kr 0.46 , while revenue for the quarter reached kr 2.57M .
EGTX.ST Stock Performance
Access detailed EGTX.ST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.